|
94
|
317
|
5ivcA |
Linked kdm5a jmj domain bound to the inhibitor n3 (4'-[(2-phenylethyl)carbamoyl][2,2'-bipyridine]-4-carboxylic acid) |
|
93
|
318
|
5iveA |
Linked kdm5a jmj domain bound to the inhibitor n8 ( 5-methyl-7-oxo-6-(propan-2-yl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-3-carbonitrile) |
|
90
|
317
|
5ivbA |
A high resolution structure of a linked kdm5a jmj domain with alpha-ketoglutarate |
|
91
|
317
|
5ivfA |
Linked kdm5a jmj domain bound to the inhibitor n10 8-(1-methyl-1h-imidazol-4-yl)-2-(4,4,4-trifluorobutoxy)pyrido[3,4-d]pyrimidin-4-ol |
|
158
|
417
|
5i96A |
Crystal structure of human mitochondrial isocitrate dehydrogenase (idh2) r140q mutant homodimer in complex with ag-221 (enasidenib) inhibitor. |
|
54
|
186
|
5hvbA |
5-methyl-6-(1-naphthylthio)thieno[2,3-d]pyrimidine 2,4-diamine |
|
57
|
186
|
5hsrA |
Fluorine substituted 5-methyl-6-(3',4'-difluoromethoxyphenythio)thieno[2,3-d]pyrimidine-2,4-diamine |
|
60
|
186
|
5hveA |
5-methyl-6-(3'-trifluromethoxyphenylthio)[2,3-d]pyrimidine 2,4-diamine |
|
50
|
186
|
5hpbA |
Human dihydrofolate reductase complex with nadph and 5-methyl-6-(phenylthio-4'trifluoromethyl)thieno[2,3-d]pyrimidine-2,4-diamine |
|
53
|
186
|
5ht5A |
6-substituted pyrrolo[2,3-d]pyrimidine 6-thieno-(4-methoxyphenyl) |
|
53
|
186
|
5huiA |
6-substituted pyrido[3,2-d]pyrimidine--6-4'-trifluoromethoxyphenyl) |
|
196
|
528
|
5hs1A |
Saccharomyces cerevisiae cyp51 (lanosterol 14-alpha demethylase) complexed with voriconazole |
|
55
|
186
|
5hqzA |
Fluorine substituted 5-methyl-6-(4'-trifluoromethoxyphenythio)thieno[2,3-d]pyrimidine-2,4-diamine |
|
53
|
186
|
5hqyA |
Human dihydrofolate reductase complex with nadph and 5-methyl-6-(2',3',4'-trifluorophenylthio)thieno[2,3-d]pyrimidine-2,4-diamine |
|
56
|
186
|
5hsuA |
Fluorine substituted 5-methyl-6-(2',4'-difluoromethoxyphenythio)thieno[2,3-d]pyrimidine-2,4-diamine |
|
139
|
365
|
4zmgA |
Crystal structure of human dihydroorotate dehydrogenase (dhodh) with dh03a338 |
|
162
|
475
|
6cizA |
Human cytochrome p450 17a1 in complex with inhibitor: abiraterone c6 nitrile |
|
42
|
159
|
6ddpA |
Mycobacterium tuberculosis dihydrofolate reductase complexed with beta-nadph and 3'-[(2r)-4-(2,4-diamino-6-ethylpyrimidin-5-yl)but-3-yn-2-yl]-5'-methoxy[1,1'-biphenyl]-4-carboxylic acid |
|
41
|
159
|
6ddsA |
Mycobacterium tuberculosis dihydrofolate reductase complexed with beta-nadph and 4-[3-[3-[2,4-bis(azanyl)-6-ethyl-pyrimidin-5-yl]prop-2-ynyl]-5-methoxy-phenyl]benzoic acid |
|
44
|
159
|
6ddwA |
Mycobacterium tuberculosis dihydrofolate reductase complexed with beta-nadph and n-(4-{[(2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}-2-hydroxybenzene-1-carbonyl)-l-glutamic acid |
|
76
|
246
|
6de5A |
Mycobacterium tuberculosis rv2671 complexed with beta-nadph and 6-ethyl-5-{(3s)-3-[2-methoxy-5-(pyridin-4-yl)phenyl]but-1-yn-1-yl}pyrimidine-2,4-diamine |
|
53
|
186
|
6de4A |
Homo sapiens dihydrofolate reductase complexed with beta-nadph and 3'-[(2r)-4-(2,4-diamino-6-ethylphenyl)but-3-yn-2-yl]-5'-methoxy-[1,1'-biphenyl]-4-carboxylic acid |
|
165
|
469
|
6cr2A |
Crystal structure of sterol 14-alpha demethylase (cyp51b) from aspergillus fumigatus in complex with the vni derivative n-(1-(2,4-dichlorophenyl)-2-(1h-imidazol-1-yl)ethyl)-4-(5-(2-fluoro-4-(2,2,2-trifluoroethoxy)phenyl)-1,3,4-oxadiazol-2-yl)benzamide |
|
158
|
475
|
6chiA |
Human cytochrome p450 17a1 in complex with inhibitor: abiraterone c6 amide |
|
157
|
474
|
6cirA |
Human cytochrome p450 17a1 in complex with inhibitor: abiraterone c6 oxime |
|
134
|
367
|
6cjfA |
Human dihydroorotate dehydrogenase bound to 4-quinoline carboxylic acid inhibitor 43 |
|
261
|
713
|
6cdqA |
Crystal structure of the w202f variant of catalase-peroxidase from b. pseudomallei with inh bound. |
|
133
|
362
|
6cjgA |
Human dihydroorotate dehydrogenase bound to napthyridine inhibitor 46 |
|
132
|
353
|
6c9bA |
The structure of mppp soaked with the products 4hka and 2ka |
|
162
|
416
|
6bl0A |
Novel modes of inhibition of wild-type idh1:direct covalent modification of his315 with cmpd11 |
|
148
|
412
|
6bkzA |
Novel modes of inhibition of wild-type idh1: non-equivalent allosteric inhibition with cmpd3 |
|
156
|
416
|
6bkyA |
Novel binding modes of inhibition of wild-type idh1: allosteric inhibition with cmpd2 |
|
159
|
416
|
6bl2A |
Novel modes of inhibition of wild-type idh1: direct covalent modification of his315 with cmpd15 |
|
160
|
416
|
6bl1A |
Novel modes of inhibition of wild-type idh1: direct covalent modification of his315 with cmpd13 |
|
158
|
414
|
6bkxA |
Novel modes of inhibition of wild-type idh1: direct covalent modification of his315 with cmpd1 |
|
170
|
492
|
6b5hA |
Aldh1a2 liganded with nad and 1-(4-cyanophenyl)-n-(3-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1h-pyrazole-4-carboxamide (compound cm121) |
|
125
|
392
|
6azwA |
Ido1/fxb-001116 crystal structure |
|
140
|
469
|
6bdhA |
Crystal structure of human cyp3a4 bound to an inhibitor |
|
157
|
468
|
6bd5A |
Crystal structure of human cyp3a4 bound to an inhibitor |
|
167
|
471
|
6bdiA |
Crystal structure of human cyp3a4 bound to an inhibitor |
|
168
|
471
|
6bdkA |
Crystal structure of human cyp3a4 bound to an inhibitor |
|
21
|
57
|
6azpB |
A structurally dynamic n-terminal region drives function of the staphylococcal peroxidase inhibitor (spin) |
|
130
|
392
|
6azvA |
Ido1/bms-978587 crystal structure |
|
174
|
492
|
6b5gA |
Aldh1a2 liganded with nad and (3-ethoxythiophen-2-yl){4-[4-nitro-3-(pyrrolidin-1-yl)phenyl]piperazin-1-yl}methanone (compound 6-118) |
|
165
|
492
|
6b5iA |
Aldh1a2 liganded with 1-(4-cyanophenyl)-n-(3-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1h-pyrazole-4-carboxamide (compound cm121) |
|
171
|
470
|
6bczA |
Crystal structure of human cyp3a4 bound to an inhibitor |
|
154
|
469
|
6bd6A |
Crystal structure of human cyp3a4 bound to an inhibitor |
|
164
|
470
|
6bd7A |
Crystal structure of human cyp3a4 bound to an inhibitor |
|
197
|
577
|
6azpA |
A structurally dynamic n-terminal region drives function of the staphylococcal peroxidase inhibitor (spin) |
|
162
|
468
|
6bd8A |
Crystal structure of human cyp3a4 bound to an inhibitor |
